Search Results - "ESTEVE, Jordi"

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia by DiNardo, Courtney D, Jonas, Brian A, Pullarkat, Vinod, Thirman, Michael J, Garcia, Jacqueline S, Wei, Andrew H, Konopleva, Marina, Döhner, Hartmut, Letai, Anthony, Fenaux, Pierre, Koller, Elizabeth, Havelange, Violaine, Leber, Brian, Esteve, Jordi, Wang, Jianxiang, Pejsa, Vlatko, Hájek, Roman, Porkka, Kimmo, Illés, Árpád, Lavie, David, Lemoli, Roberto M, Yamamoto, Kazuhito, Yoon, Sung-Soo, Jang, Jun-Ho, Yeh, Su-Peng, Turgut, Mehmet, Hong, Wan-Jen, Zhou, Ying, Potluri, Jalaja, Pratz, Keith W

“…In more than 400 older patients with AML who could not receive myeloablative therapy, the incidence of composite complete remission was higher (66.4% vs. 28.3)…”
Get full text

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia by Schmid, Christoph, Labopin, Myriam, Schaap, Nicolaas, Veelken, Hendrik, Brecht, Arne, Stadler, Michael, Finke, Juergen, Baron, Frederic, Collin, Matthew, Bug, Gesine, Ljungman, Per, Blaise, Didier, Tischer, Johanna, Bloor, Adrian, Kulagin, Aleksander, Giebel, Sebastian, Gorin, Norbert-Claude, Esteve, Jordi, Ciceri, Fabio, Savani, Bipin, Nagler, Arnon, Mohty, Mohamad

“…We report on 318 patients with acute leukemia, receiving donor lymphocyte infusion (DLI) in complete hematologic remission (CHR) after allogeneic stem cell…”
Get full text

Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study by Shouval, Roni, Labopin, Myriam, Bondi, Ori, Mishan-Shamay, Hila, Shimoni, Avichai, Ciceri, Fabio, Esteve, Jordi, Giebel, Sebastian, Gorin, Norbert C, Schmid, Christoph, Polge, Emmanuelle, Aljurf, Mahmoud, Kroger, Nicolaus, Craddock, Charles, Bacigalupo, Andrea, Cornelissen, Jan J, Baron, Frederic, Unger, Ron, Nagler, Arnon, Mohty, Mohamad

“…Allogeneic hematopoietic stem-cell transplantation (HSCT) is potentially curative for acute leukemia (AL), but carries considerable risk. Machine learning…”
Get full text

Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies by Bosch, Xavier, MD, PhD, Rovira, Montserrat, MD, PhD, Sitges, Marta, MD, PhD, Domènech, Ariadna, RN, Ortiz-Pérez, José T., MD, PhD, de Caralt, Teresa M., MD, PhD, Morales-Ruiz, Manuel, PhD, Perea, Rosario J., MD, PhD, Monzó, Mariano, MD, PhD, Esteve, Jordi, MD, PhD

“…Objectives This study sought to evaluate the efficacy of enalapril and carvedilol to prevent chemotherapy-induced left ventricular systolic dysfunction (LVSD)…”
Get full text

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients by Spyridonidis, Alexandros, Labopin, Myriam, Savani, Bipin N., Niittyvuopio, Riitta, Blaise, Didier, Craddock, Charles, Socié, Gerard, Platzbecker, Uwe, Beelen, Dietrich, Milpied, Noel, Cornelissen, Jan J., Ganser, Arnold, Huynh, Anne, Griskevicius, Laimonas, Giebel, Sebastian, Aljurf, Mahmoud, Brissot, Eolia, Malard, Florent, Esteve, Jordi, Peric, Zinaida, Baron, Frédéric, Ruggeri, Annalisa, Schmid, Christoph, Gilleece, Maria, Gorin, Norbert-Claude, Lanza, Francesco, Shouval, Roni, Versluis, Jurjen, Bug, Gesine, Fløisand, Yngvar, Ciceri, Fabio, Sanz, Jamie, Bazarbachi, Ali, Nagler, Arnon, Mohty, Mohamad

“…To address limitations of the currently used reduced-intensity/myeloablative conditioning (RIC/MAC) classification scheme we aimed to develop a tool that can…”
Get full text

Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation by Baron, Frédéric, Mohty, Mohamad, Blaise, Didier, Socié, Gérard, Labopin, Myriam, Esteve, Jordi, Ciceri, Fabio, Giebel, Sebastian, Gorin, Norbert Claude, Savani, Bipin N, Schmid, Christoph, Nagler, Arnon

“…Allogeneic hematopoietic stem cell transplantation is increasingly used as treatment for patients with life-threatening blood diseases. Its curative potential…”
Get full text

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation by Bazarbachi, Ali, Bug, Gesine, Baron, Frederic, Brissot, Eolia, Ciceri, Fabio, Dalle, Iman Abou, Döhner, Hartmut, Esteve, Jordi, Floisand, Yngvar, Giebel, Sebastian, Gilleece, Maria, Gorin, Norbert-Claude, Jabbour, Elias, Aljurf, Mahmoud, Kantarjian, Hagop, Kharfan-Dabaja, Mohamed, Labopin, Myriam, Lanza, Francesco, Malard, Florent, Peric, Zinaida, Prebet, Thomas, Ravandi, Farhad, Ruggeri, Annalisa, Sanz, Jaime, Schmid, Christoph, Shouval, Roni, Spyridonidis, Alexandros, Versluis, Jurjen, Vey, Norbert, Savani, Bipin N, Nagler, Arnon, Mohty, Mohamad

“…The ( ) gene is mutated in 25-30% of patients with acute myeloid leukemia (AML). Because of the poor prognosis associated with -internal tandem duplication…”
Get full text

Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis by BRUNET, Salut, LABOPIN, Myriam, MOHTY, Mohamad, ROCHA, Vanderson, ESTEVE, Jordi, CORNELISSEN, Jan, SOCIE, Gerard, IORI, Anna P, VERDONCK, Leo F, VOLIN, Liisa, GRATWOHL, Alois, SIERRA, Jorge

“…Patients with acute myeloid leukemia (AML) and FLT3/internal tandem duplication (FLT3/ITD) have poor prognosis if treated with chemotherapy only. Whether this…”
Get full text

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia by Brissot, Eolia, Labopin, Myriam, Beckers, Marielle M, Socié, Gérard, Rambaldi, Alessandro, Volin, Liisa, Finke, Jürgen, Lenhoff, Stig, Kröger, Nicolaus, Ossenkoppele, Gert J, Craddock, Charles F, Yakoub-Agha, Ibrahim, Gürman, Günhan, Russell, Nigel H, Aljurf, Mahmoud, Potter, Michael N, Nagler, Armon, Ottmann, Oliver, Cornelissen, Jan J, Esteve, Jordi, Mohty, Mohamad

“…This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long-term outcome of…”
Get full text

Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial by Ribera, Josep-Maria, Oriol, Albert, Morgades, Mireia, Montesinos, Pau, Sarrà, Josep, González-Campos, José, Brunet, Salut, Tormo, Mar, Fernández-Abellán, Pascual, Guàrdia, Ramon, Bernal, María-Teresa, Esteve, Jordi, Barba, Pere, Moreno, María-José, Bermúdez, Arancha, Cladera, Antonia, Escoda, Lourdes, García-Boyero, Raimundo, Del Potro, Eloy, Bergua, Juan, Amigo, María-Luz, Grande, Carlos, Rabuñal, María-José, Hernández-Rivas, Jesús-María, Feliu, Evarist

“…Minimal residual disease (MRD) is an important prognostic factor in adults with acute lymphoblastic leukemia (ALL) and may be used for treatment decisions. The…”
Get full text

Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT by Munker, Reinhold, Labopin, Myriam, Esteve, Jordi, Schmid, Christoph, Mohty, Mohamad, Nagler, Arnon

“…Mixed phenotype acute leukemias are infrequent and considered high risk. The optimal treatment approach and the role of allogeneic hematopoietic stem cell…”
Get full text

Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation by Lee, Catherine J, Savani, Bipin N, Mohty, Mohamad, Labopin, Myriam, Ruggeri, Annalisa, Schmid, Christoph, Baron, Frédéric, Esteve, Jordi, Gorin, Norbert C, Giebel, Sebastian, Ciceri, Fabio, Nagler, Arnon

“…Allogeneic blood or marrow hematopoietic cell transplantation continues to be the most potent anti-leukemic treatment for adult patients with standard,…”
Get full text

Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: A survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation by Giebel, Sebastian, Miszczyk, Leszek, Slosarek, Krzysztof, Moukhtari, Leila, Ciceri, Fabio, Esteve, Jordi, Gorin, Norbert‐Claude, Labopin, Myriam, Nagler, Arnon, Schmid, Christoph, Mohty, Mohamad

“…BACKGROUND Total body irradiation (TBI) is widely used for conditioning before hematopoietic cell transplantation. Its efficacy and toxicity may depend on many…”
Get full text

Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance by Garcia-Vidal, Carolina, Cardozo-Espinola, Celia, Puerta-Alcalde, Pedro, Marco, Francesc, Tellez, Adrian, Agüero, Daiana, Romero-Santana, Francisco, Díaz-Beyá, Marina, Giné, Eva, Morata, Laura, Rodríguez-Núñez, Olga, Martinez, Jose Antonio, Mensa, Josep, Esteve, Jordi, Soriano, Alex

“…We assess the epidemiology and risk factors for mortality of bloodstream infection (BSI) in patients with acute leukemia (AL). Prospectively collected data of…”
Get full text

Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation by Lee, Catherine J., Savani, Bipin N., Mohty, Mohamad, Gorin, Norbert C., Labopin, Myriam, Ruggeri, Annalisa, Schmid, Christoph, Baron, Frédéric, Esteve, Jordi, Giebel, Sebastian, Ciceri, Fabio, Nagler, Arnon

“…Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy generally associated with poor prognosis. Allogeneic hematopoietic cell transplantation…”
Get full text

Sorafenib improves survival of FLT3 -mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party by Bazarbachi, Ali, Labopin, Myriam, Battipaglia, Giorgia, Djabali, Azedine, Passweg, Jakob, Socié, Gerard, Forcade, Edouard, Blaise, Didier, Chevallier, Patrice, Orvain, Corentin, Cornelissen, Jan J, Arcese, William, Chantepie, Sylvain, Hashaishi, Khowla, El Cheikh, Jean, Medinger, Michael, Esteve, Jordi, Nagler, Arnon, Mohty, Mohamad

Get full text

Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development by Pérez-Amill, Lorena, Bataller, Àlex, Delgado, Julio, Esteve, Jordi, Juan, Manel, Klein-González, Nela

“…Chimeric antigen receptor (CAR) T therapies are being developed for acute myeloid leukemia (AML) on the basis of the results obtained for other haematological…”
Get full text

Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia by Canaani, Jonathan, Labopin, Myriam, Itälä-Remes, Maija, Blaise, Didier, Socié, Gerard, Forcade, Edouard, Maertens, Johan, Wu, Depei, Malladi, Ram, Cornelissen, Jan J., Huynh, Anne, Bourhis, Jean Henri, Esteve, Jordi, Mohty, Mohamad, Nagler, Arnon

“…Baseline cytogenetic studies at diagnosis remain the single most important determinant of outcome in patients with acute myeloid leukemia (AML). However, the…”
Get full text

Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation by Brissot, Eolia, Labopin, Myriam, Baron, Frédéric, Bazarbachi, Ali, Bug, Gesine, Ciceri, Fabio, Esteve, Jordi, Giebel, Sebastian, Gilleece, Maria H., Gorin, Norbert-Claude, Lanza, Francesco, Peric, Zinaida, Ruggeri, Annalisa, Sanz, Jaime, Savani, Bipin N., Schmid, Christoph, Shouval, Roni, Spyridonidis, Alexandros, Versluis, Jurjen, Nagler, Arnon, Mohty, Mohamad

Get full text

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia by Montesinos, Pau, Beckermann, Benjamin M, Catalani, Olivier, Esteve, Jordi, Gamel, Katia, Konopleva, Marina Y, Martinelli, Giovanni, Monnet, Annabelle, Papayannidis, Cristina, Park, Aaron, Récher, Christian, Rodríguez-Veiga, Rebeca, Röllig, Christoph, Vey, Norbert, Wei, Andrew H, Yoon, Sung-Soo, Fenaux, Pierre

“…Patients with refractory or relapsed acute myeloid leukemia (R/R AML) have a poor prognosis, with a high unmet medical need. Idasanutlin is a small-molecule…”
Get full text